Editorial Office, Surgery: Current Research, Belgium
Perspective
The Function of Biomarkers in Colorectal Liver Metastases Management
Author(s): Clarissa Eric*
Patients with Colorectal Liver Metastases (CRLM) now have a 5-year overall survival rate above 50% thanks to new systemic treatments paired with surgical therapy. For patients with unresectable CRLM, a wide range of liver-directed treatments have enhanced local disease control. Sadly, a sizeable percentage of patients who have curative-intent hepatectomy experience a disease recurrence. Traditional indicators do not properly risk-stratify and prognosticate CRLM patients. We now know much more about the pathophysiology and tumours microenvironment features of CRLM because to developments in molecular sequencing technologies over the past few decades. These investigations have uncovered biomarkers that could help guide treatment choices for CRLM patients. National and societal standards have taken actionable indicators including RAS and BRAF mutations, microsatellite instability/mismatc.. View More»
DOI:
10.352482161-1076.22.12(10).412
